Activation markers of coagulation

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 3, 1999, Pages 387-406

  Bauer, Kenneth A ^a,b  

^a Hematology Oncology Section   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Coagulation; Hypercoagulable state; Immunoassays; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; CONJUGATED ESTROGEN; ESTRADIOL; FIBRINOPEPTIDE A; GEMFIBROZIL; HEPARIN; LUPUS ANTICOAGULANT; WARFARIN;

ASSAY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR CLOTTING; EXTRACORPOREAL CIRCULATION; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SEPSIS; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 0033504405     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0032     Document Type: Article

References (139)

1. Gruber A, Griffin J H. Direct detection of activated protein C in blood from human subjects. Blood. 79:1992;2340-2348.
2. Orthner C L, Kolen B, Drohan W N. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo. Thrombosis and Haemostasis. 69:1993;441-447.
3. Wildgoose P, Nemerson Y, Hansen L L. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood. 80:1992;25-28.
4. Morrissey J H, Macik B G, Neuenschwander P F. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 81:1993;734-744.
5. Davie E W, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 30:1991;10363-10370.
6. Gailani D, Broze G J Jr. Factor XI activation in a revised model of blood coagulation. Science. 253:1991;909-912.
7. Ford R P, Esnouf M P, Burgess A I, Sarphie A F. An enzyme linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma. Journal of Immunoassay. 17:1996;119-131.
8. Kaplan A P, Gruber B, Harpel P C. Assessment of Hageman factor activation in human plasma: Quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood. 66:1985;636-641.
9. Minnema M C, Pajkrt D, Wuillemin W A. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood. 92:1998;3294-3301.
10. Nuijens J H, Huijbregts C CM, Eerenberg A JM. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood. 72:1988;1841-1848.
11. Wuillemin W A, Minnema M C, Meijers J CM. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C1-inhibitor. Blood. 85:1995;1517-1526.
12. Bauer K A, Kass B L, ten Cate H. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 76:1990;731-736.
13. Boisclair M D, Lane D A, Philippou H. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 82:1993;3350-3357.
14. Takahashi I, Kato K, Sugiura I. Activated factor IX-antithrombin III complexes in human blood: Quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life. Journal of Laboratory and Clinical Medicine. 118:1991;317-325.
15. Bauer K A, Kass B L, ten Cate H. Detection of factor X activation in humans. Blood. 74:1989;2007-2015.
16. 1 + 2. Journal of Biological Chemistry. 254:1979;8751-8761.
17. 1 + 2fragment and the thrombin-antithrombin complex. Blood. 59:1982;1086-1097.
18. Pelzer H, Schwart A, Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma in plasma with an antibody against a synthetic peptide. Thrombosis and Haemostasis. 65:1991;153-159.
19. 1 + 2. Thrombosis and Haemostasis. 70:1993;253-258.
20. Hursting M J, Butman B T, Steiner J P. Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay. Clinical Chemistry. 39:1993;583-591.
21. Lau H K, Rosenberg R D. The isolation and characterization of a specific antibody population directed against the thrombin-antithrombin complex. Journal of Biological Chemistry. 255:1980;5885-5893.
22. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thrombosis and Haemostasis. 59:1988;101-106.
23. Boisclair M D, Lane D A. Microtitre plate ELISA to measure thrombin-antithrombin complex using pan-specific antibodies. Blood Coagulation and Fibrinolysis. 3:1992;795-802.
24. Bauer K A, Kass B L, Beeler D L. Detection of protein C activation in humans. Journal of Clinical Investigation. 74:1984;2033-2041.
25. Espana F, Griffin J H. Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISAs. Thrombosis Research. 55:1989;671-682.
26. Espana F, Vicente V, Tabernero D. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thrombosis Research. 59:1990;593-608.
27. Hoogendoorn H, Nesheim M E, Giles A R. A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood. 75:1990;2164-2171.
28. 2-M) by ELISA in patients with disseminated intravascular coagulation (DIC). Blood. 78:1991;74a.
29. Nossel H, Younger L, Wilner G. Radioimmunoassay of human fibrinopeptide A. Proceedings of the National Academy of Sciences of the USA. 68:1971;2350-2353.
30. Nossel H L, Yudelman I, Canfield R E. Measurement of fibrinopeptide A in human blood. Journal of Clinical Investigation. 54:1974;43-53.
31. Cronlund M, Hardin J, Burton J. Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosis. Journal of Clinical Investigation. 58:1976;142-151.
32. Nossel H L, Ti M, Kaplan K L. The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity. Journal of Clinical Investigation. 58:1976;1136-1144.
33. Kockum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite. Thrombosis Research. 19:1980;589-598.
34. Soria J, Soria C, Ryckewaert J J. A solid phase immuno enzymological assay for the measurement of human fibrinopeptide A. Thrombosis Research. 20:1980;425-435.
35. Woodhams B J, Kernoff P BA. Rapid radioimmunoassay for fibrinopeptide A in plasma. Thrombosis Research. 22:1981;407-416.
36. Bauer K A, Weiss L M, Sparrow D. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study. Journal of Clinical Investigation. 80:1987;1527-1534.
37. Hursting M J, Stead A, Crout F. Effects of age, race, sex and smoking on plasma prothrombin fragment F1.2 (F1.2) levels in a healthy population. Blood. 76:1990;423a.
38. Mari D, Mannucci P M, Coppola R. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 85:1995;3144-3149.
39. Bartsch P, Haeberli A, Straub P W. Blood coagulation after long distance running: antithrombin III prevents fibrin formation. Thrombosis and Haemostasis. 63:1990;430-434.
40. Miller G J, Bauer K A, Cooper J A, Rosenberg R D. Activation of the coagulant pathway in cigarette smokers. Thrombosis and Haemostasis. 79:1998;549-553.
41. Caine Y G, Bauer K A, Barzegar S. Coagulation activation following estrogen administration to postmenopausal women. Thrombosis and Haemostasis. 68:1992;392-395.
42. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thrombosis and Haemostasis. 71:1994;420-423.
43. Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post-menopausal women. A randomized controlled trial. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;3071-3078.
44. 1 + 2concentration, a marker of coagulability, in patients with coronary heart disease. Thrombosis and Haemostasis. 67:1992;503-506.
45. Miller G J, Martin J C, Mitropoulos K A. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood. 87:1996;4187-4196.
46. Kapur R, Hoffman C J, Bhushan V, Hultin M B. Postprandial elevation of elevated factor VII in young adults. Arteriosclerosis, Thrombosis and Vascular Biology. 16:1996;1327-1332.
47. Silveira A, Karpe F, Johnsson H, Bauer K A, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arteriosclerosis, Thrombosis and Vascular Biology. 16:1996;1333-1339.
48. Weinstein M J, Chute L E, Schmitt G W. Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. Jounral of Clinical Investigation. 76:1985;1406-1411.
49. 2-macroglobulin, in patients with disseminated intravascular coagulation. Thrombosis and Haemostasis. 69:1993;448-453.
50. Bauer K A, Rosenberg R D. Thrombin generation in acute promyelocytic leukemia. Blood. 64:1984;791-796.
51. Asakura H, Saito M, Ito K. Levels of thrombin-antithrombin III complex in plasma in cases of acute promyelocytic leukemia. Thrombosis Research. 50:1988;895-899.
52. Hoek J A, Sturk A, ten Cate J W. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clinical Chemistry. 34:1988;2058-2062.
53. Boisclair M D, Lane D A, Wilde J T. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. British Journal of Haematology. 74:1990;471-479.
54. Neame P B, Kelton J G, Walker I R. Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood. 56:1980;88-92.
55. Bilezikian S B, Nossel H L, Butler V P Jr. Radioimmunoassay of human fibrinopeptide B and kinetics of cleavage by different enzymes. Journal of Clinical Investigation. 56:1975;438-445.
56. Nossel H L, Wasser J, Kaplan K L. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. Journal of Clinical Investigation. 64:1979;1371-1378.
57. Eckhardt T, Nossel H L, Hurlet-Jensen A. Measurement of desarginine fibrinopeptide B in human blood. Journal of Clinical Investigation. 67:1981;809-816.
58. Nossel H L. Relative proteolysis of the fibrinogen Bb-chain as a determinant of thrombosis. Nature. 291:1981;165-167.
59. Owen J, Kvam D, Nossel H L. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood. 61:1983;476-482.
60. Boneu B, Bes G, Pelzer H. D-dimers, thrombin antithrombin III complexes and prothrombin fragments 1 + 2: diagnostic value in clinically suspected deep vein thrombosis. Thrombosis and Haemostasis. 65:1991;28-31.
61. Estivals M, Pelzer H, Sie P. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. British Journal of Haematology. 78:1991;421-424.
62. Yudelman I M, Nossel H L, Kaplan K L. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood. 51:1978;1189-1195.
63. Yudelman I, Greenberg J. Factors affecting fibrinopeptide-A in levels in patients with venous thromboembolism during anticoagulant therapy. Blood. 59:1982;787-792.
64. Hoek J A, Nurmohamed M T, ten Cate J W. Thrombin-antithrombin III complexes in the prediction of deep vein thrombosis following total hip replacement. Thrombosis and Haemostasis. 62:1989;1050-1052.
65. van Deventer S JH, Buller H R, ten Cate J W. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 76:1990;2520-2526.
66. Suffredini A F, Harpel P C, Parrillo J E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. New England Journal of Medicine. 320:1989;1165-1172.
67. Michie H R, Manogue K R, Spriggs D R. Detection of circulating tumor necrosis factor after endotoxin administration. New England Journal of Medicine. 318:1988;1481-1486.
68. ten Cate J W, van der Poll T, Levi M. Cytokines: triggers of clinical thrombotic disease. Thrombosis and Haemostasis. 78:1997;415-419.
69. Bauer K A, ten Cate H, Barzegar S. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 74:1989;165-172.
70. van der Poll T, Buller H R, ten Cate H. Coagulation activation following tumor necrosis factor administration to normal subjects. New England Journal of Medicine. 322:1990;1622-1627.
71. Levi M, ten Cate H, Bauer K A. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in a chimpanzee model. Journal of Clinical Investigation. 93:1994;114-120.
72. Bauer K A, Mannucci P M, Gringeri A. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood. 79:1992;2039-2047.
73. Eichinger S, Mannucci P M, Tradati F. Determinants of plasma factor VIIa levels in humans. Blood. 86:1995;3021-3025.
74. ten Cate H, Bauer K A, Levi M. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. Journal of Clinical Investigation. 92:1993;1207-1212.
75. Ruf W, Edgington T S. An anti-tissue factor monoclonal antibody which inhibits TF-VIIa complex is a potent anticoagulant in plasma. Thrombosis and Haemostasis. 66:1991;529-533.
76. Bauer K A, Broekmans A W, Bertina R M. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood. 71:1988;1418-1426.
77. Mannucci P M, Tripodi A, Bottasso B. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thrombosis and Haemostasis. 67:1992;200-202.
78. Martinelli I, Bottasso B, Duca F. Heightened thrombin generation in individuals with resistance to activated protein C. Thrombosis and Haemostasis. 75:1996;703-705.
79. Conard J, Bauer K A, Gruber A. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 82:1993;1159-1164.
80. Zöller B, Holm J, Svensson P. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thrombosis and Haemostasis. 75:1996;270-274.
81. Bauer K A, Goodman T L, Kass B L. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. Journal of Clinical Investigation. 76:1985;826-836.
82. 1 + 2measurements. Thrombosis Research. 63:1991;617-628.
83. Boisclair M D, Philippou H, Lane D A. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coagulation and Fibrinolysis. 4:1993;1007-1021.
84. Demers C, Ginsberg J S, Henderson P. Measurements of markers of activated coagulation in antithrombin III deficient subjects. Thrombosis and Haemostasis. 67:1992;542-544.
85. Ginsberg J S, Demers C, Brill-Edwards P. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood. 81:1993;2958-2963.
86. Tripodi A, Mannucci P M, Chantarangkul V. Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. British Journal of Haematology. 84:1993;670-674.
87. Neri Serneri G G, Gensini G F, Abbate R. Is raised plasma fibrinopeptide A a marker of acute coronary insufficiency? Lancet. ii:1980;982.
88. Theroux P, Latour J G, Leger-Gautier C. Fibrinopeptide A plasma levels and platelet factor 4 levels in unstable angina pectoris. Circulation. 75:1987;156-162.
89. van Hulsteijn H, Kolff J, Briet E. Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. American Heart Journal. 107:1984;39-45.
90. Wilensky R L, Bourdillon P D, Vix V A, Zeller J A. Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical and angiographic correlation. Journal of the American College of Cardiology. 21:1993;692-699.
91. Ardissino D, Gamba M G, Merlini P A. Fibrinopeptide A excretion in urine: a marker of cumulative thrombin activity in stable versus unstable angina patients. American Journal of Cardiology. 68:1991;58B-63B.
92. Fuster V, Badimon L, Badimon J J, Chesebro J H. Mechanism of disease: the pathogenesis of coronary artery disease and the acute coronary syndromes. New England Journal of Medicine. 326:1994;242-250.
93. Merlini P A, Bauer K A, Oltrona L. Persistent activation of the coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68.
94. Mizuno K, Satumora K, Miyamoto A. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. New England Journal of Medicine. 326:1992;287-291.
95. Ardissino D, Merlini P A, Gamba G. Thrombin activity and early outcome in unstable angina pectoris. Circulation. 93:1996;1634-1639.
96. Granger C B, Becker R, Tracy R P. Thrombin generation, inhibition, and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-1 trial. Journal of the American College of Cardiology. 31:1998;497-505.
97. Miller G J, Bauer K A, Barzegar S. Increased activation of the hemostatic system in men at high risk of fatal coronary artery disease. Thrombosis and Haemostasis. 75:1996;767-771.
98. Marmur J D, Merlini P A, Sharma S K. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. Journal of the American College of Cardiology. 24:1994;1484-1491.
99. Ardissino D, Merlini P A, Ariens R. Tissue factor antigen and activity of human coronary atherosclerotic plaques. Lancet. 349:1997;769-771.
100. Oltrona L, Eisenberg P R, Lasala J M. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation. 94:1996;2064-2071.
101. Stoddard M F, Dawkins P R, Prince C R, Ammash N M. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. Journal of the American College of Cardiology. 25:1995;452-459.
102. Oltrona L, Broccolino M, Merlini P A. Activation of the hemostatic mechanism following pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation. 95:1997;2003-2006.
103. Mombelli G, Im Hof V, Haeberli A. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation. 69:1984;684-689.
104. Gallino A, Haeberli A, Hess T. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effect of intravenous and subcutaneous low-dose heparin. American Heart Journal. 112:1986;285-290.
105. Neri Serneri G G, Gensini G, Poggesi L. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina. Lancet. 335:1990;615-618.
106. Merlini P A, Ardissino D, Bauer K A. Persistent thrombin generation during heparin therapy in acute coronary syndromes. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;1325-1330.
107. Zoldhelyi P, Bichler J, Owen W G. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation. 90:1994;2671-2678.
108. Granger C B, Miller J M, Bovill E G. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 92:1995;1929-1935.
109. Gold H K, Torres F W, Garaberian H D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. Journal of the American College of Cardiology. 21:1993;1039-1047.
110. Theroux P, Waters D, Lam J. Reactivation of unstable angina after discontinuation of heparin. New England Journal of Medicine. 327:1992;141-145.
111. Eisenberg P R, Sherman L A, Jaffe A S. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence of continued thrombosis despite intense fibrinolysis. Journal of the American College of Cardiology. 10:1987;527-529.
112. Owen J, Friedman K D, Grossman B A. Thrombolytic therapy with tissue-type plasminogen activator or streptokinase induced transient thrombin activity. Blood. 72:1988;616-620.
113. Baglin T P, Luddington R, Jennings I, Richards E M. Thrombin generation and myocardial infarction during infusion of tissue-plasminogen activator. Lancet. 1:1993;504-505.
114. Genser N, Mair J, Maier J. Thrombin generation during infusion of tissue-type plasminogen activator. Lancet. 1:1993;1038.
115. Merlini P A, Cattaneo M, Spinola A. Activation of the hemostatic system during thrombolytic therapy. American Journal of Cardiology. 72:1993;59G-65G.
116. Rapold H J, deBono D, Arnold A ER. Plasma fibrinopeptide A levels in patients with myocardial infarction treated with alteplase. Circulation. 85:1992;928-934.
117. Merlini P A, Bauer K, Oltrona L. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. Journal of the American College of Cardiology. 25:1995;203-209.
118. Gulba D C, Barthels M, Westhoff-Bleck M. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation. 83:1991;937-944.
119. Merlini P A, Ardissino D, Bauer K. Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Blood. 86:1995;3327-3332.
120. Peuscher F W, van Aken W G, Flier O TN. Effect of anticoagulant treatment measured by fibrinopeptide A (fpA) in patients with venous thrombo-embolism. Thrombosis Research. 18:1980;33-43.
121. Teitel J M, Rosenberg R D. Protection of factor Xa from neutralization by the heparin-antithrombin complex. Journal of Clinical Investigation. 71:1983;1383-1391.
122. Conway E M, Bauer K A, Barzegar S. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. Journal of Clinical Investigation. 80:1987;1535-1544.
123. Mannucci P M, Bottasso B, Tripodi A. Prothrombin fragment 1 + 2 and intensity of treatment with oral anticoagulants. Thrombosis and Haemostasis. 66:1991;741.
124. Elias A, Bonfils S, Daoud-Elias M. Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thrombosis and Haemostasis. 69:1993;302-305.
125. 1 + 2levels. Blood. 79:1992;2034-2038.
126. Harenberg J, Haas R, Zimmermann R. Plasma hypercoagulability after termination of oral anticoagulants. Thrombosis Research. 29:1983;627-633.
127. Swars H, Hafner G, Erbel R. Prothrombin fragment and thrombotic occlusion of coronary stents. Lancet. 337:1991;59.
128. Hafner G, Swars H, Erbel R. On the possibility to reduce subacute occlusion after coronary stenting by measurement of the prothrombin fragment 1 + 2. Annals of Haematology. 65:1992;153-159.
129. Haude M, Hafner G, Jablonka A. Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1 + 2. American Heart Journal. 130:1994;228-238.
130. Hardin J A, Cronlund M, Haber E. Activation of blood clotting in patients with systemic lupus erythematosus. Relationship to disease activity. American Journal of Medicine. 65:1978;430-436.
131. Leeksma O C, Stoepman-van Dalen E A, van Ginkel C JW. A reappraisal of FPA immunoreactivity in cancer patients. Thrombosis and Haemostasis. 50:1983;400.
132. Myers T J, Rickles F R, Barb C. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood. 57:1981;518-525.
133. Gugliotta L, Vigano S, D'Angelo A. High fibrinopeptide A (FPA) levels in acute non-lymphocytic leukemia are reduced by heparin administration. Thrombosis and Haemostasis. 52:1984;301-304.
134. Leichtman D, Brewer G. Elevated plasma levels of fibrinopeptide A during sickle cell anemia pain crisis - evidence for intravascular coagulation. American Journal of Hematology. 5:1978;183-190.
135. Green D, Scott J P. Is sickle cell crisis a thrombotic event? American Journal of Hematology. 23:1986;317-321.
136. Francis R, Patch J, McGehee W. Elevated prothrombin F 1.2 fragment in sickle cell disease: further evidence for activation of coagulation in the steady state. Blood. 76:1990;61a.
137. Bauer K A, Rosenberg R D. Assays for thrombin generation in humans with prethrombotic states. Thrombosis and Haemostasis. 50:1983;159.
138. Mannucci P M, Bauer K A, Gringeri A. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood. 76:1990;2540-2545.
139. Mannucci P M, Bauer K A, Gringeri A. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. British Journal of Haematology. 79:1991;606-611.